Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
11 shown of 6,086 total abstracts
  1. Abstract 68662026-06-02 · 16:15 CT · Hall B1
    KEYNOTE-972: Keytruda (pembrolizumab) adjuvant in RCC
    L. Paz-Ares, M. Reck, G. Curigliano, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  2. Abstract 62252026-06-03 · 21:00 CT · S100A
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-195
    C. Saura, C. Robert, S. Peters, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  3. Abstract 63992026-06-04 · 14:45 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in RCC
    M. Reck, M.C. Garassino · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  4. Abstract 69042026-06-05 · 20:15 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-378
    G. Curigliano, S. Antonia, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  5. Abstract 65292026-06-05 · 15:00 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-191 study)
    T. Mok, S. Modi · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  6. Abstract 60682026-06-04 · 18:15 CT · Arie Crown Theater
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-933
    S. Tolaney, C. Saura, M. Reck, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  7. Abstract 66122026-06-05 · 19:15 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-311
    H. Rugo, S. Antonia · Massachusetts General Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  8. Abstract 69822026-06-01 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-779
    A. Spira, T. Mok, J. Cortes, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  9. Abstract 61652026-06-02 · 15:45 CT · S406
    Quality of life outcomes with Opdivo in patients with RCC
    S. Tolaney, M. Krop, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  10. Abstract 68002026-06-05 · 14:00 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-71 study)
    P. Schmid, S. Modi, J. Cortes · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  11. Abstract 66382026-06-02 · 14:00 CT · E450
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-773
    S. Tolaney, C. Robert, H. Borghaei, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.